BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
Developed using STEERLife’s proprietary FragMelt continuous processing platform, the approval marks a major breakthrough in pharmaceutical manufacturing
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Subscribe To Our Newsletter & Stay Updated